Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year High on Analyst Upgrade

Shares of Bicara Therapeutics Inc. (NASDAQ: BCAX - Get Free Report) reached a new 52-week high on Wednesday after The Goldman Sachs Group raised their price target on the stock from $14.00 to $16.00. The Goldman Sachs Group currently has a neutral rating on the stock. Bicara Therapeutics traded as high as $21.05 and last traded